Core Viewpoint - The company, Haichuang Pharmaceutical, anticipates a reduction in losses for the fiscal year 2025, with projected net losses between 150 million to 125 million yuan, representing a year-on-year decrease in losses of approximately 24.81% to 37.34% [2][6]. Group 1: Performance Forecast - The company expects a total profit loss of 150 million to 125 million yuan for 2025, a reduction in losses compared to the previous year by 49.48 million to 74.48 million yuan [2]. - The projected net profit attributable to the parent company is also expected to be between 150 million to 125 million yuan, with a similar reduction in losses compared to the previous year [2]. - The anticipated operating revenue for 2025 is estimated to be between 19 million to 22 million yuan, with the same range applicable for revenue excluding non-core business income [2]. Group 2: Previous Year Performance - In 2024, the company reported an operating revenue of 366,800 yuan, with a total profit loss of 199.48 million yuan and a net profit loss attributable to the parent company of 199.49 million yuan [4]. Group 3: Reasons for Performance Changes - The approval and market launch of the company's first Class 1 new drug, Deuteroenzalutamide soft capsule, in May 2025 is expected to contribute to increased sales revenue compared to the previous year [5]. - The inclusion of Deuteroenzalutamide soft capsule in the National Medical Insurance Drug List is anticipated to lead to a significant price reduction, affecting revenue projections due to inventory adjustments and changes in marketing strategies [5]. - The company plans to reduce research and development expenses for 2025 to between 105 million to 125 million yuan, a decrease from the previous year [5].

Core Viewpoint - The company is expected to report a net loss of 125 million to 150 million yuan for the year 2025 due to various factors affecting its revenue and expenses [1] Group 1: Performance Forecast - The company anticipates a net profit loss of 125 million to 150 million yuan for the full year of 2025 [1] - The expected operating revenue for 2025 is projected to be between 19 million and 22 million yuan, primarily due to limited sales from its first Class 1 new drug, HC-1119, and the impact of its inclusion in the National Medical Insurance Drug List [1] - The company plans to reduce R&D expenses to between 105 million and 125 million yuan in 2025, a decrease of 49.03 million to 69.03 million yuan compared to the previous year [1] Group 2: Q3 2025 Financial Results - For the first three quarters of 2025, the company's main revenue reached 23.35 million yuan, a significant increase of 21,180.28% year-on-year [2] - The net profit attributable to shareholders for the same period was -99.15 million yuan, reflecting a year-on-year increase of 35.65% [2] - The company reported a gross margin of 99.57% for Q3 2025, with a single-quarter main revenue of 10.18 million yuan [2]